Metabolic (Dysfunction)-Associated Fatty Liver Disease in Chinese Patients with Type 2 Diabetes from a Subcenter of the National Metabolic Management Center

Figure 2

(a) Proportions of patients having plasma AST or ALT in total MAFLD, lean, nonobese, and obese MAFLD. (b) Distributions of noninvasive liver fibrosis scores in MAFLD patients. (c) Proportions of patients having “intermediate” risk of fibrosis for each score in lean, nonobese, and obese MAFLD patients. (d) Proportions of patients having “high” risk of fibrosis for each score in lean, nonobese, and obese MAFLD patients. AST: aspartic acid aminotransferase; ALT: alanine aminotransferase; APRI: AST-to-platelet ratio index; FIB-4: fibrosis-4 index; NFS: nonalcoholic fatty liver disease fibrosis score.

(a)

(b)

(c)

(d)